Medicare Plans Could Gain Drug Pricing Leverage under CMS Proposal
For the sake of fostering competition among drug makers, the Centers for Medicare & Medicaid Services proposed Monday to give Medicare Part D plans greater leeway to decline to cover certain protected-class drugs beginning in 2020.
